Drugs / GSK-065
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03245619 | Aug 2017 → May 2018 | acute necrotizing pancreatitis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK-065 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4091152 ↗ |
| Known as | GSK3335065 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03245619 ↗ |
| Modality | Small molecule | — CHEMBL4091152 ↗ |
| Route | Intravenous | “GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL” NCT03245619 ↗ |